Treatment Results and Malignant Complications in Patients on Long-Term Treatment with Tyrosine Kinase Inhibitors(TKIs) for Chronic Myeloid Leukemia(CML)

Taiichi Kyo(Hiroshima University), Keiko Ohtani, Hideki Asaoku(Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital), Tetsurou Ohti(Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital), Ryouta Imanaka(Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital), Takesi Okatani(Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital), Mitsuhiro Itagaki(Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital), Kouji Iwato(Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital), Yuuta Katayama(Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital), Megu Ohtaki(Hiroshima University), Kouhei Kyo(Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital)
Blood
November 16, 2012
10.1182/blood.v120.21.3767.3767
Cited by 1

Related Papers

Apparent Diffusion Coefficient of Human Brain Tumors at MR Imaging
|Radiology|2005|505
High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia
|Blood|2003|277
Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis
|The Lancet|2007|242
Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study
|The Lancet|2008|126
Lymphomas and glioblastomas: Differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3 T
|European Journal of Radiology|2010|113